NeuroSense Faces Nasdaq Compliance Warning
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy NRSN?
Source: seekingalpha
- Compliance Warning: NeuroSense Therapeutics received notifications from Nasdaq indicating non-compliance with minimum bid price requirements, as its shares traded below $1.00 for 30 consecutive business days from February 18 to March 31, highlighting potential listing risks for the company.
- Market Value Decline: During the same period, NeuroSense's market value of listed securities also fell below the $35 million threshold, which not only impacts the company's market perception but may also negatively affect investor confidence.
- Trading Continuity: Despite the compliance notices, NeuroSense stated that its securities will continue to trade on Nasdaq, indicating that the company still has time and opportunity to regain compliance and avoid delisting risks.
- Compliance Deadline: The company must regain compliance by September 29, 2026, including maintaining a share price above $1.00 and a market value above $35 million for at least 10 consecutive business days, which will significantly impact its future financial performance and strategic planning.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NRSN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NRSN
Wall Street analysts forecast NRSN stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.760
Low
7.50
Averages
8.25
High
9.00
Current: 0.760
Low
7.50
Averages
8.25
High
9.00
About NRSN
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NeuroSense Faces Nasdaq Compliance Warning
- Compliance Warning: NeuroSense Therapeutics received notifications from Nasdaq indicating non-compliance with minimum bid price requirements, as its shares traded below $1.00 for 30 consecutive business days from February 18 to March 31, highlighting potential listing risks for the company.
- Market Value Decline: During the same period, NeuroSense's market value of listed securities also fell below the $35 million threshold, which not only impacts the company's market perception but may also negatively affect investor confidence.
- Trading Continuity: Despite the compliance notices, NeuroSense stated that its securities will continue to trade on Nasdaq, indicating that the company still has time and opportunity to regain compliance and avoid delisting risks.
- Compliance Deadline: The company must regain compliance by September 29, 2026, including maintaining a share price above $1.00 and a market value above $35 million for at least 10 consecutive business days, which will significantly impact its future financial performance and strategic planning.
See More
NeuroSense Faces Nasdaq Compliance Warning
- Compliance Warning: NeuroSense received two notification letters from Nasdaq on April 2, 2026, indicating non-compliance with continued listing requirements, which could negatively impact its market reputation and investor confidence.
- Price Below Requirement: The company's ordinary shares closed below $1 for 30 consecutive business days from February 18 to March 31, 2026, violating Nasdaq Listing Rule 5550(a)(2), raising concerns about its future performance among investors.
- Market Value Insufficiency: Additionally, NeuroSense's market value fell below $35 million during the same period, failing to meet Nasdaq Rule 5550(b)(2), which may restrict its financing capabilities and affect future business expansion.
- Compliance Period: The company has a compliance period of 180 days until September 29, 2026, to regain compliance with both the bid price and market value requirements; failure to do so may lead to delisting risks, impacting long-term shareholder value.
See More
NeuroSense Reports FY 2025 Financial Results with Patent Grant
- Financial Performance: NeuroSense Therapeutics reported a GAAP EPS of $0.44 for FY 2025; however, the operating loss widened to $11.09 million from $9.90 million in 2024, indicating ongoing financial strain.
- Cash Position: As of December 31, 2025, NeuroSense reported approximately $0.20 million in cash, suggesting challenges in liquidity that could impact future operations and R&D capabilities.
- Patent Approval: NeuroSense was granted a U.S. patent for its Alzheimer's disease treatment, which not only enhances the company's technological barriers but also potentially provides a significant competitive edge in the market.
- Market Reaction: Despite advancements in patent approvals, the ongoing losses and cash flow issues may negatively affect investor confidence, leading to stock price volatility.
See More
NeuroSense Reports 2025 Financial Results and Business Update
- Significant Clinical Progress: In 2025, NeuroSense successfully advanced PrimeC from Phase 2 to a late-stage clinical asset, with the PARADIGM study demonstrating approximately a 33% slowdown in disease progression, establishing a strong competitive position in the ALS market.
- Survival Data Breakthrough: Early in 2026, NeuroSense reported a 65% reduction in death risk and a median survival benefit exceeding 14 months from its Phase 2 study, potentially enhancing PrimeC's market appeal and investor confidence.
- Clear Regulatory Path: The company received FDA clearance in November 2025 to initiate the PARAGON Phase 3 trial, marking a key inflection point in its ALS treatment development, expected to accelerate PrimeC's market entry process.
- Improved Financial Position: Research and development expenses for 2025 were $6.2 million, an 8.8% increase from 2024, indicating NeuroSense's commitment to ongoing investment in future growth despite rising costs in the biotechnology sector.
See More
NeuroSense to Present PrimeC Data at AD/PD 2026 Conference
- Clinical Data Presentation: Dr. Christian Lunetta, Chief Medical Officer of NeuroSense, will present new clinical and biomarker data on PrimeC at the 2026 AD/PD International Conference, highlighting its potential in ALS treatment and likely attracting significant attention from the scientific community.
- PARADIGM Trial Findings: The presentation will review key findings from the Phase 2b PARADIGM trial, which provide an important scientific foundation for the design of the global Phase 3 PARAGON trial, potentially accelerating the path to market authorization for PrimeC.
- ALS Disease Burden: Over 5,000 people are diagnosed with ALS annually in the U.S., with the number of patients expected to grow by 24% by 2040, underscoring NeuroSense's strategic importance in addressing this significant unmet medical need.
- Global Trial Plans: The PARAGON Phase 3 trial is planned as a multinational, randomized, double-blind, placebo-controlled study designed to further evaluate PrimeC's potential to slow disease progression in ALS patients, demonstrating NeuroSense's commitment to advancing innovative therapeutic options.
See More
NeuroSense Publishes ALS Clinical Trial Results in JAMA Neurology
- Clinical Trial Results: NeuroSense's PARADIGM Phase 2b trial results indicate that the PrimeC treatment group achieved a 7.92-point improvement in functional scores over 18 months, representing over a 36% slowdown in disease progression, laying a solid foundation for further Phase 3 trials.
- Biomarker Changes: The trial observed significant improvements in iron metabolism biomarkers, including the preservation of transferrin levels and stabilization of ferritin, indicating PrimeC's effectiveness in modulating ALS-related biological pathways.
- Safety and Tolerability: The study results demonstrated good safety for PrimeC, with multiple clinical endpoints consistently suggesting potential clinical benefits, thereby enhancing confidence in its role as a disease-modifying therapy.
- Future Development Plans: NeuroSense has received FDA clearance to proceed with a Phase 3 trial aimed at validating PrimeC's impact on ALS patients, further advancing its clinical development trajectory.
See More
NeuroSense Faces Nasdaq Compliance Warning
- Compliance Warning: NeuroSense Therapeutics received notifications from Nasdaq indicating non-compliance with minimum bid price requirements, as its shares traded below $1.00 for 30 consecutive business days from February 18 to March 31, highlighting potential listing risks for the company.
- Market Value Decline: During the same period, NeuroSense's market value of listed securities also fell below the $35 million threshold, which not only impacts the company's market perception but may also negatively affect investor confidence.
- Trading Continuity: Despite the compliance notices, NeuroSense stated that its securities will continue to trade on Nasdaq, indicating that the company still has time and opportunity to regain compliance and avoid delisting risks.
- Compliance Deadline: The company must regain compliance by September 29, 2026, including maintaining a share price above $1.00 and a market value above $35 million for at least 10 consecutive business days, which will significantly impact its future financial performance and strategic planning.
See More
NeuroSense Faces Nasdaq Compliance Warning
- Compliance Warning: NeuroSense received two notification letters from Nasdaq on April 2, 2026, indicating non-compliance with continued listing requirements, which could negatively impact its market reputation and investor confidence.
- Price Below Requirement: The company's ordinary shares closed below $1 for 30 consecutive business days from February 18 to March 31, 2026, violating Nasdaq Listing Rule 5550(a)(2), raising concerns about its future performance among investors.
- Market Value Insufficiency: Additionally, NeuroSense's market value fell below $35 million during the same period, failing to meet Nasdaq Rule 5550(b)(2), which may restrict its financing capabilities and affect future business expansion.
- Compliance Period: The company has a compliance period of 180 days until September 29, 2026, to regain compliance with both the bid price and market value requirements; failure to do so may lead to delisting risks, impacting long-term shareholder value.
See More
NeuroSense Reports FY 2025 Financial Results with Patent Grant
- Financial Performance: NeuroSense Therapeutics reported a GAAP EPS of $0.44 for FY 2025; however, the operating loss widened to $11.09 million from $9.90 million in 2024, indicating ongoing financial strain.
- Cash Position: As of December 31, 2025, NeuroSense reported approximately $0.20 million in cash, suggesting challenges in liquidity that could impact future operations and R&D capabilities.
- Patent Approval: NeuroSense was granted a U.S. patent for its Alzheimer's disease treatment, which not only enhances the company's technological barriers but also potentially provides a significant competitive edge in the market.
- Market Reaction: Despite advancements in patent approvals, the ongoing losses and cash flow issues may negatively affect investor confidence, leading to stock price volatility.
See More
NeuroSense Reports 2025 Financial Results and Business Update
- Significant Clinical Progress: In 2025, NeuroSense successfully advanced PrimeC from Phase 2 to a late-stage clinical asset, with the PARADIGM study demonstrating approximately a 33% slowdown in disease progression, establishing a strong competitive position in the ALS market.
- Survival Data Breakthrough: Early in 2026, NeuroSense reported a 65% reduction in death risk and a median survival benefit exceeding 14 months from its Phase 2 study, potentially enhancing PrimeC's market appeal and investor confidence.
- Clear Regulatory Path: The company received FDA clearance in November 2025 to initiate the PARAGON Phase 3 trial, marking a key inflection point in its ALS treatment development, expected to accelerate PrimeC's market entry process.
- Improved Financial Position: Research and development expenses for 2025 were $6.2 million, an 8.8% increase from 2024, indicating NeuroSense's commitment to ongoing investment in future growth despite rising costs in the biotechnology sector.
See More
NeuroSense to Present PrimeC Data at AD/PD 2026 Conference
- Clinical Data Presentation: Dr. Christian Lunetta, Chief Medical Officer of NeuroSense, will present new clinical and biomarker data on PrimeC at the 2026 AD/PD International Conference, highlighting its potential in ALS treatment and likely attracting significant attention from the scientific community.
- PARADIGM Trial Findings: The presentation will review key findings from the Phase 2b PARADIGM trial, which provide an important scientific foundation for the design of the global Phase 3 PARAGON trial, potentially accelerating the path to market authorization for PrimeC.
- ALS Disease Burden: Over 5,000 people are diagnosed with ALS annually in the U.S., with the number of patients expected to grow by 24% by 2040, underscoring NeuroSense's strategic importance in addressing this significant unmet medical need.
- Global Trial Plans: The PARAGON Phase 3 trial is planned as a multinational, randomized, double-blind, placebo-controlled study designed to further evaluate PrimeC's potential to slow disease progression in ALS patients, demonstrating NeuroSense's commitment to advancing innovative therapeutic options.
See More
NeuroSense Publishes ALS Clinical Trial Results in JAMA Neurology
- Clinical Trial Results: NeuroSense's PARADIGM Phase 2b trial results indicate that the PrimeC treatment group achieved a 7.92-point improvement in functional scores over 18 months, representing over a 36% slowdown in disease progression, laying a solid foundation for further Phase 3 trials.
- Biomarker Changes: The trial observed significant improvements in iron metabolism biomarkers, including the preservation of transferrin levels and stabilization of ferritin, indicating PrimeC's effectiveness in modulating ALS-related biological pathways.
- Safety and Tolerability: The study results demonstrated good safety for PrimeC, with multiple clinical endpoints consistently suggesting potential clinical benefits, thereby enhancing confidence in its role as a disease-modifying therapy.
- Future Development Plans: NeuroSense has received FDA clearance to proceed with a Phase 3 trial aimed at validating PrimeC's impact on ALS patients, further advancing its clinical development trajectory.
See More
